Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.

HuidaGene Presents Late-Breaking Data at World Muscle Society 2024 Demonstrating HG302 CRISPR/hfCas12Max DNA-Editing Therapy for Duchenne Muscular Dystrophy to Support M.U.S.C.L.E. Clinical Trial

2024.09.24 09:00
Views:449
Follow Us on Social Media
g3icon09.svg
g3icon08.svg
g3icon010.svg
  • HG302, a single AAV system packaging the compact, high-fidelity Cas12Max, meditates a single-cut in-vitro genome editing efficiency of over 60% in the human DMD exon 51 splice-donor.

  • Systemic delivery of HG302 in humanized DMD mice efficiently restored dystrophin expression and rescued motor function, including rotarod and grip strength tests, to wild-type levels.

  • HG302 induced therapeutically acceptable editing efficiency at the exon 51 splice-donor site in non-human primates with no observed drug-related toxicity.

  • M.U.S.C.L.E.an open-label, Multidose dose-escalation study to Understand the Safety of Crispr gene-editing therapy and its long-Lasting Effects in DMD is the world’s first-in-human CRISPR/DNA genome-editing trial beyond Cas9 for DMD.


SHANGHAI and CLINTON (NJ), September 24, 2024 - HuidaGene Therapeutics (“HuidaGene”), a global clinical-stage biotechnology company developing potentially curative genome medicines, today announced the presentation of the CRISPR/hfCas12Max® supporting the clinical development of HG302 to treat Duchenne muscular dystrophy (DMD) as a late-breaking abstract at the 29th Annual Congress of the World Muscle Society, taking place in Prague, Czechia, from October 8 to 12, 2024.


The novel high-fidelity Cas12i variant (hfCas12Max) discovered through HuidaGene’s proprietary AI-guided HG-PRECISE® platform exhibits the highest on-target editing efficiency and lowest off-targeting activity in mammalian cells compared to widely used SpCas9 or other Cas12a/b/e systems while packaging into a single viral vector. The USPTO granted Cas12i a patent with strong intellectual property protection. Systemically delivered by a single ‘all-in-one’ AAV system, HG302 induced the hfCas12Max-mediated single-cut genome editing in human DMD exon 51 splice-donor sites with a one-time intravenous injection to treat DMD patients. 1.pngHG302 CRISPR-based DNA-editing therapy has been granted both orphan drug and rare pediatric disease designations for treating DMD patients amenable to exon 51 skipping by the U.S. FDA. Details on late-breaking abstract:

Title: 719LP - Duchenne Muscular Dystrophy Gene Editing Therapy with CRISPR/high-fidelity Cas12Max

Location/Date: The Prague Congress Centre, Forum Hall - 11th October 2024 


“Several industry-sponsored AAV-mediated micro-dystrophin gene replacement therapy trials observed serious adverse events, including liver toxicity, myocarditis, thrombocytopenia, and death at high doses ranging from 1.3E14 to 3E14 vg/kg,” said Alvin Luk, Ph.D., MBA, CCRA, Co-Founder and Chief Executive Officer of HuidaGene. "Our high editing efficiency and minimal off-target activity of hfCas12Max allow us to dose HG302 at the E13 vg/kg range, a 10-fold lower than current ongoing DMD clinical trials. The M.U.S.C.L.E. clinical study (NCT06594094) currently recruits ambulant DMD boys with measurably impaired muscle function.”


About HuidaGene

HuidaGene utilizes its proprietary CRISPR-based HG-PRECISE® platform to discover, engineer, and develop genome medicine. The Company is advancing clinical programs of HG004 (granted ODD & RPDD by FDA) ‘LIGHT’ trial (NCT06088992) and Phase 1/2 international, master-protocol ‘STAR’ clinical trial (NCT05906953) in RPE65-associated inherited retinal disease, HG202 RNA-editing therapy ‘SIGHT-I’ trial (NCT06031727) for neovascular age-related macular degeneration, HG204 RNA-editing therapy (granted ODD & RPDD by FDA and ODD by EMA) ‘HERO’ trial for MECP2 duplication syndrome, as well as HG302 DNA-editing therapy (granted ODD & RPDD by FDA) first-in-human ‘MUSCLE’ trial (NCT06594094) for Duchenne muscular dystrophy, and the preclinical pipeline, including HG303 DNA-editing for Amyotrophic Lateral Sclerosis, and CRISPR RNA-editing therapy for Alzheimer’s disease. HuidaGene’s extensive intellectual property portfolio positions it as a leader in unleashing the full potential of genome medicines for neurology and ophthalmology. Learn more at huidagene.com or on LinkedIn.